Pages Menu
Twitter
Categories Menu

Posted by on May 29, 2008 in Neurology

NSAID Reduction of AD Not Dependent on Suppression of Beta Amyloid

NSAID Reduction of AD Not Dependent on Suppression of Beta Amyloid

Ibuprofen_web.jpg

Last year, Johns Hopkins investigators found that use of NSAIDs reduced the risk of Alzheimer’s disease by 37%. Closer examination of the data (from the Cardiovascular Health Cognition Study) revealed that the protective benefit of NSAIDs was confined to those individuals with an ApoE4 allele; however, the benefit was not attributable to the suppression of Aβ1-42 amyloid

Then earlier this month, a review of Veterans Affairs records showed that long-term use of NSAIDs reduced the odds of AD by 24%, and that a more substantial risk reduction was observed with ibuprofen and naproxen (odds reduction, 37%). However, like the Hopkins study, the Veterans records did not indicate a particular benefit with those NSAIDs that suppress Aβ1-42 amyloid.

Now comes a follow-up report from the same Hopkins investigators, who pooled data from 6 prospective studies* (N = 13,499). Again, the investigators found that the use of NSAIDs reduced the risk of AD by approximately one third. And also again, the risk reduction with NSAIDs that suppress Aβ1-42 amyloid was not higher than that with nonsuppressing NSAIDs. A substantial risk reduction with aspirin, but not acetaminophen, was also observed.

*Baltimore Longitudinal Study of Aging, Cache County Study, Canadian Study of Health and Aging, Cardiovascular Health Study, Framingham Heart Study, and Monongahela Valley Independent Elders Study.

Photo: iStockPhoto.

bmartin (1127 Posts)

A native East Tennessean, Barbara Martin is a formerly practicing, board-certified neurologist who received her BS (psychology, summa cum laude) and MD from Duke University before completing her postgraduate training (internship, residency, fellowship) at the Hospital of the University of Pennsylvania in Philadelphia. She has worked in academia, private practice, medical publishing, drug market research, and continuing medical education (CME). For the last 3 years, she has worked in a freelance capacity as a medical writer, analyst, and consultant. Follow Dr. Barbara Martin on and Twitter.